Avidity Biosciences Past Earnings Performance
Past criteria checks 0/6
Avidity Biosciences's earnings have been declining at an average annual rate of -41.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 6% per year.
Key information
-41.9%
Earnings growth rate
24.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 6.0% |
Return on equity | -20.7% |
Net Margin | -2,381.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely
Mar 26Avidity Biosciences: Risks And Potential
Dec 09We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Nov 30Revenue & Expenses Breakdown
How Avidity Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 11 | -252 | 64 | 0 |
31 Mar 24 | 11 | -229 | 56 | 0 |
31 Dec 23 | 10 | -212 | 54 | 0 |
30 Sep 23 | 10 | -202 | 48 | 0 |
30 Jun 23 | 10 | -193 | 45 | 0 |
31 Mar 23 | 10 | -192 | 41 | 0 |
31 Dec 22 | 9 | -174 | 38 | 0 |
30 Sep 22 | 8 | -162 | 35 | 0 |
30 Jun 22 | 8 | -148 | 31 | 0 |
31 Mar 22 | 8 | -128 | 29 | 0 |
31 Dec 21 | 9 | -118 | 26 | 0 |
30 Sep 21 | 10 | -96 | 24 | 0 |
30 Jun 21 | 9 | -78 | 21 | 0 |
31 Mar 21 | 8 | -62 | 17 | 0 |
31 Dec 20 | 7 | -44 | 13 | 0 |
30 Sep 20 | 6 | -38 | 10 | 0 |
30 Jun 20 | 5 | -34 | 7 | 0 |
31 Mar 20 | 4 | -28 | 6 | 0 |
31 Dec 19 | 2 | -25 | 5 | 0 |
31 Dec 18 | 0 | -11 | 2 | 0 |
Quality Earnings: RNA is currently unprofitable.
Growing Profit Margin: RNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNA is unprofitable, and losses have increased over the past 5 years at a rate of 41.9% per year.
Accelerating Growth: Unable to compare RNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: RNA has a negative Return on Equity (-20.68%), as it is currently unprofitable.